Clinical and non-clinical use of MDMA.
Tidsskr Nor Laegeforen June 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al.
Clinical and non-clinical use of MDMA.
Lowan H. Stewart
7 papers in the library · 33 citations · publishing 2018-2026
Papers
Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).
J Affect Disord May 16, 2026 David S. Mathai, Madeleine Cluck, Amna M. Aslam et al. 1 citation
Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).
MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial
Journal of Psychiatric Research November 27, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Joanna Róg et al. 3 citations
BACKGROUND: Major depressive disorder (MDD) is a leading cause of global disability, and current treatments often fail to provide sustained effectiveness. MDMA-assisted therapy (MDMA-AT) is a promising treatment for MDD. However, the long-term effects are not known. OBJECTIVES: To examine the long-term effects of MDMA-AT for MDD. METHODS: Twelve participants with MDD and an ongoing moderate to...
Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample.
Frontiers in Pharmacology 2025 Paula Aarseth Tunstad, Tor-Morten Kvam, Malin V. Uthaug et al. 2 citations
Interest in the therapeutic effects of classical psychedelics has risen recently. However, little epidemiological knowledge exists about the use of classical psychedelics in Scandinavian countries. Additionally, there is a limited understanding of what factors drive self-reported improvement in wellbeing. The aim of this study was to investigate the relationship between the use of classical...
Assessment of psychedelic--induced states: Norwegian translation and adaptation of the revised Mystical Experience Questionnaire (MEQ-30)
Journal of Psychedelic Studies July 12, 2024 Kristoffer Andreas Aamodt Andersen, Bjørn Holmøy, Lowan H. Stewart 1 citation
Abstract Background Previous international clinical trials have indicated that mystical experiences resulting from the consumption of classic psychedelic drugs, such as psilocybin, may represent a subjective psychological mechanism of action associated with therapeutic effects for various mental disorders. The revised 30-item Mystical Experience Questionnaire is one of several psychometric...
Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”
Frontiers in Psychiatry October 26, 2022 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al. 11 citations
Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the...
Psykedeliske stoffer i behandling av angst, depresjon og avhengighet
Tidsskrift for Den norske legeforening 2018 Tor-Morten Kvam, Lowan H. Stewart, Ole A. Andreassen 15 citations
Psykedeliske stoffer i behandling av flere psykiske lidelser har vist lovende resultater, men studiene er små og har metodologiske utfordringer. Det er behov for systematiske kliniske studier for å skaffe solid dokumentasjon for effekt og etablere rutiner for overvåkning av mulige bivirkninger.